Silica in oral drugs as a possible sarcoidosis-inducing antigen.
Solà
Rosa
R
Boj
Montserrat
M
Hernandez-Flix
Salvador
S
Camprubí
Mercé
M
D000284:Administration, Oral; D000941:Antigens / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000737:chemistry*; D017298:Bisoprolol / Q000737:chemistry; D015984:Causality; D002626:Chemistry, Pharmaceutical; D017292:Doxazosin / Q000737:chemistry; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014677:Pharmaceutical Vehicles / Q000009:adverse effects*; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced* / Q000175:diagnosis; D012822:Silicon Dioxide / Q000009:adverse effects*; D013777:Tetrazoles / Q000737:chemistry; D014633:Valine / Q000031:analogs & derivatives / Q000737:chemistry; D000068756:Valsartan
D000941:Antigens; D000959:Antihypertensive Agents; D014677:Pharmaceutical Vehicles; D013777:Tetrazoles; D012822:Silicon Dioxide; D000068756:Valsartan; D014633:Valine; D017292:Doxazosin; D017298:Bisoprolol